Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-DAPPER for Depression and PTSD in Kenya
NCT03466346Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of fluoxetine in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (5 arms), sponsored by University of California, San Francisco. Primary endpoints: Number of Participants With Major Depression at End of Treatment at 12 months and Number of Participants With PTSD at 12 months. Started Aug 2020; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03466346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466346.